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Abstract Increased expression of multidrug-resistance
associated protein 1 in brain tissue has been reported which
lead to multidrug resistance of refractory epilepsy. How-
ever, the mechanism of up-regulated expression is still
unclear. In our previous study, we have found that the
MAPK signaling pathway mediated the expression of
P-glycoprotein. So in this study, we used a rat model of
refractory epilepsy to examine whether p38 MAPK affect
the expression of MRP1 and the concentrations of AEDs in
the brain. The expression of MRP1 and p38 MAPK was
detected by immunofluorescence, Western-blot and real
time-PCR, while the concentration of AEDs was measured
by microdialysis and HPLC. The result showed that
SB202190, the specific inhibitor of p38 MAPK, could
down-regulate the expression of MRP1, while increase the
concentrations of valproate and lamotrigine in hippocam-
pus extracellular fluid of refractory epileptic rat. We
demonstrate that p38 MAPK signaling pathway may be
involved in drug resistance of refractory epilepsy by reg-
ulating MRP1.
Keywords p38 MAPK  Refractory epilepsy  Drug
resistance  Multidrug resistance-associated protein 1
Introduction
Refractory epilepsy is a common neurologic disease but
remains a major medical intractability that accounts for
approximately one-third of epileptic patients with resis-
tance to several, if not all, antiepileptic drugs (AEDs), even
though these drugs act by different mechanisms [1, 2].
The therapeutic effect of treatment of epilepsy is limited by
the development of multidrug resistance, which mainly
induced by intrinsic or acquired overexpression of efflux
pumps in the blood–brain barrier (BBB), such as P-gly-
coprotein and multidrug-resistance associated protein 1
(MRP1) [3]. Therefore, the search for down-regulation
expression of multidrug resistance transporter is a rational
approach to solve the drug resistance. p38 MAPK is a
member of the MAPK family, which produce certain bio-
logical effects through the activation of some transcription
factors and other proteases. There is now some evidences
that inhibition of the p38 MAPK signaling pathway down-
regulated P-gp expression and diminished the cellular
multidrug resistance [4–6]. In addition, there was showed
that p38 MAPK and ERK were involved in the resistance
of cells to mercury by expression MRP1 in AML-2/DX100
cells [7]. The above suggest that p38 MAPK signaling
pathway may be involved in the drug resistance of mul-
tidrug transporter mediated refractory epilepsy and plays
an important role. In this study, the expression of MRP1 in
the brain of refractory epilepsy rat was investigated, while
the effect of the inhibition of p38 MAPK on the concen-
trations of two AEDs, VPA and LTG [8], in hippocampal
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was demonstrated that whether p38 MAPK is involved in
drug resistance of refractory epilepsy through regulation
the expression of MRP1.
Materials and Methods
Chemicals
Pentylenetetrazol (PTZ), phenytoin (PHT), sodium val-
proate (VPA), lamotrigine (LTG), Dapi, and SB202190
were purchased from Sigma-Aldrich Co. (St. Louis, MO,
USA). Mouse monoclonal antibody against MRP1 was
purchased from Abcam plc. (Cambridge Science Park,
Cambridge, UK). Rabbit monoclonal antibody against p38
MAPK was obtained from Cell Signaling Technology Inc.
(Danvers, MA, USA). Mouse monoclonal antibody against
phosphorylate-p38 (p-p38), mouse polyclonal antibody
against GAPDH, goat anti-mouse IgG-HRP and goat anti-
rabbit IgG-HRP were obtained from Santa Cruz Biotech-
nology Inc. (Santa Cruz, CA, USA). DyLightTM488-con-
jugated affinipure goat anti-mouse IgG and DyLightTM594-
conjugated affinipure goat anti-rabbit IgG were from
Jackson Immuno Research laboratories, Inc. (West Grove,
PA, USA). TRIzolTM reagent and a reverse transcription
system were purchased from Promega (Madison, WI,
USA). Sequences of oligonucleotide primers for real time-
PCR analysis were synthesized by Bio TNT Inc. (Shanghai,
China). PrimeScriptTM RT master mix and PrimeScriptTM
RT reagent kit with gDNA Eraser were purchased from
TaKaRa (Otsu Shiga, Japan). Microdialysis probe, micro-
dialysis cannula and CMA/100 micro-injection pump came
from CMA Inc. (Derwood, MD, USA). MonEL510 high
performance liquid chromatography was made from Bei-
jing Syltech Scientific Instrument Co. (Ltd, Beijing,
China).
Animals and Grouping
Male Wistar rats (weighing 200–250 g) were purchased
from SIPPR/BK laboratory animal Ltd (Shanghai, China).
All animal experiments were approved by the Guideline for
Animal Experiments of the Chinese. The rats were housed
in standard animal-grade room with one animal in each
cage. The temperature was maintained at 20 ± 2 C, the
relative moisture at 60 %, and the light cycle at 12 h/day.
The rats were allowed to adapt to the new conditions for at
least 1 week before being used in the experiments.
Animals were randomly divided into three groups:
control group, refractory epilepsy group (epilepsy group)
and SB202190 group. The refractory epileptic rats were
administrated with SB202190 by the microdialysis probe in
the SB202190 group, while artificial cerebrospinal fluid
was administrated by microdialysis in epilepsy group. Each
group included eight rats.
Establishing of a Epileptic Rat Model
Rats were intraperitoneally injected with 1 % PTZ at
40 mg/kg body weight every other day for 14–20 days [9].
After PTZ injection, their behavior was continuously
observed for a period of 30 min. Seizure severity was
evaluated according to the standards of Racine [10]. Rats
with three consecutive stage V seizures were considered to
be successfully kindled. In total, thirty-two rats were suc-
cessful kindled, the success rate was 72.7 %.
Drug Screening
Then epileptic rats were intraperitoneally injected with
PHT (62.5 mg/kg body weight), and were screened for
drug resistance. According to the after discharge threshold
(ADT), the rats with 100 % increase of ADT after drug
administration were considered drug sensitive epileptic
rats. Whereas, refractory epileptic rats were ADT did not
increase or only increased up to 20 % after drug
administration.
Establishing a Microdialysis System
Microdialysis was established based on previous studies
[11]. The animals were implanted with microdialysis can-
nula into the hippocampus. The cannula was fixed to the
skull with dental acrylic cement. The coordinates were
2.0 mm lateral and 3.0 mm posterior to bregma and
3.5 mm ventral starting from the dura according to the
animal anatomy atlas. After connecting the microdialysis
device, animals received continuous unilateral intrahip-
pocampal perfusion of artificial cerebrospinal fluid at a
constant flow rate (2.0 ll/min), then balanced for 1 h to
make the substance exchange tends of cerebrospinal fluid
within the probe and the hippocampus extracellular fluid to
be stable. SB202190 (4 mmol/l) was injected through the
microdialysis probe (2.0 ll/min) for half an hour before
administrating AEDs in SB202190 group. Finally, 20 ll of
exchanged effluent dialysate were collected at various time
points (0, 30, 60, 90, 120 and 150 min) after intraperitoneal
injection of 200 mg/kg VPA and 10 mg/kg LTG. Micro-
dialysate samples were stored at -80 C and used for
HPLC detection in 2 weeks. Because the permeability of
semi permeable membrane was different for each drug, the
actual concentration of AEDs in hippocampal extracellular
fluid was equal to the concentration of AEDs in dialysate/
recovery efficiency of microdialysis probe in vitro.
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Measuring Drug Concentration Using Dialysate
by High-Performance Liquid Chromatography
Concentrations of VPA and LTG in dialysate were detected
using HPLC. A 20 ll sample was directly injected into the
chromatograph (MODEL 510). Chromatographic conditions
were as follows: Ultimate XB-C8 column (150 mm 9
4.6 mm, 5 lm particle size, for detecting VPA), Dikma C18
column (150 mm 9 4.6 mm, 5 lm particle size, for detect-
ing LTG). Mobile phase, methanol/water (55:45, v:v); flow
rate, 1.0 ml per minute; ultraviolet wavelength of detection,
210 nm; column temperature, 30 C; Detector, L-2400 UVD;
Column oven, L-2300; Pump, L-2130.
Immunofluorescence Staining
Frozen Sects. (30 lm) of rat brain tissue were incubated
with anti-MRP1 antibody (1:50 dilution, Abcam plc.) and
anti-p38 antibody (1:50 dilution, Cell Signaling Technol-
ogy Inc.) at 4 C overnight. Then the sections were incu-
bated with DyLightTM488-conjugated affinipure secondary
antibody (1:500 dilution, Jackson Immuno Research labo-
ratories, Inc.) and DyLightTM594-conjugated affinipure
secondary antibody (1:300 dilution, Jackson Immuno
Research laboratories, Inc.) at 37 C for an hour. After that,
the sections were incubated with DAPI (1:10,000 dilution,
Sigma-Aldrich Co.) at 37 C for 20 min. After sections
were mounted and sealed, the results were observed using a
fluorescence microscope.
Western Blotting
Proteins isolated from the hippocampus and cerebral
cortex tissue were resolved by SDS-PAGE and transferred
to polyvinylidene fluoride (PVDF) membranes. The
membranes were incubated with primary antibodies (anti-
MRP1 antibody 1:500, dilution, Abcam plc.; anti-p38
MAPK antibody, 1:1000 dilution, Cell Signaling Tech-
nology Inc.; anti-p-p38 antibody, 1:1000, dilution, Santa
Cruz Biotechnology Inc.; and anti-GAPDH antibody,
1:30,000 dilution, Santa Cruz Biotechnology Inc.) at 4 C
overnight and subsequently horseradish peroxidase-con-
jugated secondary antibodies at room temperature for 2 h.
Specific proteins were visualized with enhanced chemi-
luminescence detection reagent and determined by an
Image Quant LAS4000 mini chemiluminescence imaging
system with QUANTITY ONE software (Bio-Rad Labo-
ratories, Hercules, CA, USA).
Real Time-PCR
Total RNA was extracted from fresh brain tissue using the
TRIzol method. RNA samples were reverse-transcribed to
generate first-strand complementary DNA (cDNA). cDNAs
were prepared by first strand cDNA synthesis kit according
to the protocol. The primers for MRP1, p38, and b-actin were
designed by BioTNT Inc. (Shanghai, China). The sequences
of gene-specific primers were: MRP1 (ABCC1)-forward: 50-
CGAATGTCCTCTGAGATGGAGAC-30, reverse: 50-CTCT
ACACGGCCTGAATGGG-30 [12]. b-actin-forward: 50-GA
GCTACGAGCTGCCTGACG-30, reverse: 50-GTAGTTTCG
TGGATGCCACAG-30. p38 (MAPK14)- forward: 50-CGAG
CGATACCAGAACCTGT-30, reverse: 50-GCGTGAATGA
TGGACTGAAA-30. The cycling parameters were as fol-
lows: initial denaturation at 95 C for 10 min, followed by
40 cycles of denaturation 95 C for 30 s, annealing at 58 C
for 1 min, extension at 72 C for 1 min. A standard curve
and a melting curve were created automatically when the
reactions were completed. The mRNA levels of the target
genes were quantified with SYBR Green-based real time-
PCR analysis (Bio-Rad) and analyzed using the delta delta
CT method (DDCT) as described and the target amount =
2DDCT [13].
Statistical Analysis
Data analysis was made using SPSS11.5. The data are pre-
sented as the mean ± standard error. The comparison between
samples was examined using the paired t test or a one-way
ANOVA. Significance was assumed for p values\0.05.
Results
Down-Regulation of MRP1 Expression in Cortex
and Hippocampus of Epileptic Rats
Immunofluorescence staining showed that the expression
of MRP1 could be observed in the hippocampus and
cerebral cortex of rats in each group. The Immunofluo-
rescence images labeled with p38 MAPK (red) exhibiting
cytoplasmic location in the control group and nuclear
location in the epilepsy and SB202190 groups, while the
membrane location for MRP1 (green) and the nuclear
location for Dapi (blue) were observed in each group. The
MRP1 and p38 MAPK-positive cells were significantly
higher in both cortex and hippocampus CA1 region in
epilepsy group than those in control group (p\ 0.01).
Compared with the epilepsy group, the number of MRP1
and p38 MAPK-positive cells were significantly decreased
in SB202190 group (p\ 0.05; Fig. 1a, b).
Similarly, Western blot results showed that the expres-
sion of MRP1, p38 and p-p38 protein was significantly
increased in the hippocampus and cortex in epilepsy group
compared with the control group (p\ 0.01). After
SB202190 administration, the protein expression of MRP1,
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p38 and p-p38 decreased significantly compared with that
in the epilepsy group (p\ 0.05; Fig. 2a, b).
Finally, quantitative real time-PCR (qPCR) analysis
revealed that the mRNA expression of MRP1 was signifi-
cantly higher in the hippocampus and cortex in epilepsy
group than that in control group (ratiohippocampus =
2.0070 ± 0.28301, ratiocortex = 4.3231 ± 0.74318), and
the same as the mRNA expression of p38 (ratiohippocampus =
1.6947 ± 0.08200, ratiocortex = 1.6155 ± 0.23264). For
the SB202190 group, the mRNA expression of MRP1 and
p38 was lower than that in the epilepsy group (p\ 0.05;
Fig. 3).
SB202190 Decreased Seizures Level and Frequency
of Epileptic Rat
Through the analysis of the behavior in rats of refractory
epilepsy, we found that before the treatment of SB202190,
seizures levels were all above stage III, which contained 10
times stage III seizures, 17 times stage IV seizures and 18
times stage V seizures. While after the administration of
SB202190, most seizures were at stage IV, with one time
stage II seizure, 12 times stage V seizures and 11 times
stage III seizures. It showed that seizures level and fre-
quency in the SB202190 group were decreased than that in
the epilepsy group (p\ 0.05; Table 1).
SB202190 Increased VPA Concentration
in the Hippocampal Extracellular Fluid of Epileptic
Rat
VPA was detected in the hippocampal extracellular fluid 30
min after administration in each group. In the control
group, the highest concentrations of VPA in the hip-
pocampal extracellular fluid was 13.69 ± 0.48 lg/ml at
30 min post-injection (Fig. 4). Both the epilepsy and the
SB202190 group, VPA reached a peak at 60 min and
gradually decreased thereafter. However, the concentra-
tions of VPA in the hippocampal extracellular fluid in the
epilepsy group were significantly lower at each time point
(p = 0.000, 0.023, 0.000, 0.000 and 0.002, respectively)
compared with those in the control group. In addition,
SB202190, a specific p38 MAPK inhibitor, significantly
increased VPA concentration in the hippocampal extra-
cellular fluid at each time point post-injection in the
SB202190 group (p = 0.001, 0.000, 0.001, 0.035 and
0.039 vs. the epilepsy group, respectively). The result
indicated that the administration of SB202190 did not
change the trend of fluctuation of VPA, but significantly
increased the concentrations of VPA in the hippocampal
extracellular fluid of epileptic rats.
SB202190 Increased LTG Concentration
in the Hippocampal Extracellular Fluid of Epileptic
Rat
Similarly, LTG was detected in the hippocampal extra-
cellular fluid 30 min after administration in each group. In
the control group, the highest concentrations of LTG in the
hippocampal extracellular fluid was 73.87 ± 2.98 ng/ml at
60 min post-injection (Fig. 5). Both the epilepsy and the
SB202190 group, LTG reached a peak at 90 min and
gradually decreased thereafter. The LTG level found in the
hippocampal extracellular fluid in the epilepsy group was
much lower than those in the control group at each time
point over 30–150 min (p = 0.000, 0.000, 0.002, 0.000 and
Fig. 1 a MRP1 and p38 MAPK expression in the rat brain
(fluorescence microscope 4009). a Cortex of the control group;
b Cortex of the epilepsy group; c Cortex of the SB202190 group;
d Hippocampus CA1 region of the control group; e Hippocampus
CA1 region of the epilepsy group; f Hippocampus CA1 region of the
SB202190 group. b Quantitative analysis of immunofluorescence.
MRP1-positive and p38 MAPK-positive cells were counted and at
least 3 slices from each brain were measured. **p\ 0.01 compared
with the control group; 4p\ 0.05 compared with the epilepsy group
Neurochem Res (2015) 40:1546–1553 1549
123
0.006, respectively). Moreover, SB202190 administration
significantly increased LTG concentrations in the hip-
pocampal extracellular fluid at each time point in the
SB202190 group (p = 0.007, 0.006, 0.007, 0.010 and
0.046 vs. epilepsy group, respectively). The result indi-
cated that the administration of SB202190 did not change
the trend of fluctuation of LTG, but significantly increased
the concentrations of LTG in the hippocampal extracellular
fluid of epileptic rats.
Discussion
Almost 30 % of patients with epilepsy are resistant to
AEDs therapy [14]. The mechanism of drug resistance is
unclear, and likely to be multifactorial, but may include
Fig. 2 a MRP1 and p38 MAPK
protein expression in the rat
brain. b Quantitative analysis of
western blot. **p\ 0.01,
*p\ 0.05 compared with the
control group; 4p\ 0.05
compared with the epilepsy
group
Fig. 3 Quantitative analysis of real-time PCR. The target mRNA
expression of the control group was recruited as 1. **p\ 0.01,
*p\ 0.05 compared with the epilepsy group
Fig. 4 Concentration of VPA in the hippocampal extracellular fluid
Table 1 The effect of SB202190 on the behavior in epilepsy rats
Grading according













* p\ 0.05 compared with the epilepsy group
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alterations of pharmacological targets and poor penetration
of AEDs into the brain because of increased expression of
multiple drug-resistance proteins, such as P-glycoprotein
and MRP1. MRP1, also known as ABCC1, belongs to the
ATP-binding cassette superfamily, which is an important
multidrug transporter in the brain [15–17]. It is encoded by
a gene located in chromosome 16p13.1 [18] and involved
in chemotherapy drug resistance because of its three
membrane-spanning domains and two nucleotide-binding
domains [19, 20]. The outwardly directed active efflux
mechanism, either by extracellular drug export or by
intracellular vesicular sequestration, appears to act as an
active defense mechanism for limiting brain accumulation
of many lipophilic drugs [19, 21, 22]. There is accumu-
lating evidences that overexpression of MRP1 was found in
the brain of patients with refractory epilepsy [23, 24]. In
addition, several studies have shown that the overexpres-
sion of MRP1 causes resistance to antiepileptic drugs [25,
26], due to its function as an efflux pump to transfer AEDs
out of the brain tissue or cells [27]. MRP2, another trans-
porter of AEDs in the brain, found mainly in the luminal
surface of brain capillary endothelium, whereas other
MRPs, such as MRP3 and MRP5, are located basolaterally
[28]. It was determined that increased expression of the
gene encoding MRP2 by using gene arrays to study
mRNAs of multidrug transporters in endothelial cells iso-
lated from surgically resected epileptic foci of patients with
pharmacoresistant partial epilepsy [23]. Subsequently, it
was shown by other groups that, the concentration of PHT
in the brain of MRP2-deficient rats was significantly higher
than in the wild-type rats [29], indicating that MRP2 sub-
stantially contributes to BBB function.
Most experimental and clinical studies on the multidrug-
transporter hypothesis of intractable epilepsy have exam-
ined the expression and function of P-gp in the brain,
whereas only relatively few studies dealt with other mul-
tidrug transporters, such as MRP1 or MRP2. So in our
study, we choose MRP1 as the target transporter. In our
early studies, we had found that probenecid, MRP inhi-
bitor, significantly increased the concentration of LTG in
the extracellular fluid of the hippocampus [30]. For the
chosen of AEDs, as we know, the combination of sodium
valproate with lamotrigine demonstrating synergism. And
VPA belongs to I generation AEDs, while LTG belongs to
II generation AEDs. So we choose these two AEDs.
Mitogen-activated protein kinase (MAPK) is an impor-
tant signaling pathway, which are activated by different
extracellular stimuli or by signal transduction from the cell
surface to the nucleus. In addition, the regulated MAPK
cascade reaction system is involved in cell proliferation,
differentiation, apoptosis, migration, invasion and inflam-
mation [31]. There are 5 main subgroups manipulating by a
set of sequential actions: ERK (ERK1/ERK2), c-Jun N
(JNK/SAPK), p38 MAPK (p38a, p38b, p38c and p38d),
ERK3/ERK4 and ERK5 [31, 32]. p38 MAPK, discovered
in 1993 [33] is selectively activated by MAPK kinases
(MKK3/6) [34] and the mechanism is mediated by dual
phosphorylation at the Thr-Gly-Tyr motif.
Some recent data showed that blocking the p38 MAPK
pathway could down-regulated P-gp expression and reverse
the cellular multidrug resistance [4–6]. And it was shown
by other groups that the p38 MAPK and ERK pathway
were involved in the resistance of cells to mercury by
regulation the expression of MRP1 [7]. The mechanism by
which MRP1 is overexpressed in the epileptic brain may be
similar to PGP, although MRP1 is only 15 % homologous
in amino acid sequence to PGP. Their substrates are close
and have a considerable overlap [35]. So in the present
study, we chose MRP1 as the target protein and applied
SB202190, a p38 MAPK specific antagonist [36] as in our
previous study [5].
Our data of this study showed that the expression of
MRP1 and p38 MAPK in brain of refractory epileptic rats
were significantly increased compared with the control
group, which could be down-regulated with SB202190.
Compared with the control, the concentration of VPA and
LTG in hippocampal extracellular fluid in the epilepsy
group were lower during 30–150 min after i.p., and, the
concentration of VPA and LTG in hippocampal extracel-
lular fluid in the SB202190 group were higher during
30–150 min after i.p. compared with the epilepsy group. In
addition, seizures level and frequency in the SB202190
group were decreased than that in the epilepsy group. So in
sum, it has demonstrated that SB202190 significantly
decreased MRP1 expression and up-regulated the VPA and
LTG concentrations in the hippocampal extracellular fluid
of refractory epileptic rats.
All above findings reveal that p38 MAPK might be
involved in drug resistance of refractory epilepsy by reg-
ulation of MRP1 expression. Further research will be
helpful for understanding the mechanism of drug resistanceFig. 5 Concentration of LTG in the hippocampal extracellular fluid
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in refractory epilepsy and provide novel therapeutic
approaches to refractory epilepsy.
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